$BMRN News
Last published 1w ago
- 1w agoBMRNBIOMARIN PHARMACEUTICAL INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoBMRNBioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry DiseasePR NewswireAgreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry diseaseBioMarin will make an upfront payment of $70
- 2w agoBMRNBioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ETPR NewswireSAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and
- 1mo agoBMRNBioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual MeetingPR NewswireNew analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infantsSAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin
- 1mo agoBMRNBioMarin Appoints Cara Bauer as Chief People OfficerPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D., has been named Executive Vice President, Chief People Officer. Ms....
- 1mo agoBMRNBioMarin reports five-year Pompe disease data showing durable motor functionCNBCBioMarin shared five-year data showing a combination therapy helped adults with late-onset Pompe disease maintain motor function.
- 1mo agoBMRNBioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual CongressPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) +...
- 1mo agoBMRNBioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of DirectorsPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D., to the company's Board of Directors, ...
- 2mo agoBMRNBioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM EvidencePR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO® (vosoritide) in children ...
- 2mo agoBMRNBioMarin to Participate in Upcoming Investor ConferencesPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September. An audio...
- 2mo agoBMRNBioMarin Announces Close of the Alesta Therapeutics AcquisitionPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Alesta Therapeutics. The...
- 2mo agoBMRNBioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South KoreaPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ...
- 2mo agoBMRNBioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's PipelinePR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics to...
- 3mo agoBMRNBioMarin Reports Second Quarter 2026 Financial and Operating ResultsPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30, 2026. "This quarter, we executed...
- 3mo agoBMRNBioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ETPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
- 3mo agoBMRNBioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU SyndromePR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and n-Lorem Foundation, a nonprofit organization, today announced a strategic collaboration and global...
- 4mo agoBMRNU.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With AchondroplasiaPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental...
- 4mo agoBMRNBioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026PR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the...
- 5mo agoBMRNBioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with HypochondroplasiaPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 CANOPY-HCH-3 study evaluating treatment with VOXZOGO® (vosoritide) in...
- 5mo agoBMRNBioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 DeficiencyPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from the pivotal Phase 3 ENERGY 3 trial evaluating BMN 401 in children aged 1-12...
- 6mo agoBAXBMRNBXLT4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of DirectorsBusiness WireFinancing to accelerate 4D Path's pipeline of treatment predictive biomarkers in solid tumors. 4D Path adds two seasoned healthcare executives to strengthen its board and accelerate growth. Ms. Stultz to serve as 4D
- 6mo agoBMRNBioMarin Reports First Quarter 2026 Financial and Operating ResultsPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the first quarter ended March 31, 2026. "With the acquisition of...
- 6mo agoBMRNBioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual MeetingPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new research from studies of VOXZOGO® (vosoritide) in children with achondroplasia...
- 6mo agoBMRNBioMarin Completes Acquisition of Amicus TherapeuticsPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Amicus Therapeutics for $14.50 ...
- 6mo agoBMRNBioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ETPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
- 6mo agoBMRNBioMarin Announces Board Leadership TransitionPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that the Board of Directors has appointed Ian T. Clark as Chair of the Board, subject to his...
- 8mo agoBMRNBioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics MeetingPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive new data from studies of VOXZOGO® (vosoritide) in children with achondroplasia...
- 8mo agoBMRNU.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)PR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental...
- 8mo agoBMRNBioMarin to Participate in Four Upcoming Investor Conferences in MarchPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will participate in four upcoming investor conferences in March. TD Cowen 46th ...
- 8mo agoBMRNBioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating ResultsPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2025. "In 2025, ...
- 8mo agoBMRNPTCTPhenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsightPR NewswireRecently published Phenylketonuria Market Insights report includes a comprehensive understanding of current treatment practices, phenylketonuria...
- 8mo agoBMRNBioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ETPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
- 9mo agoBMRNBioMarin Announces Closing of Private Offering of Senior NotesPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it closed its previously announced offering of $850 million of 5.500%...
- 9mo agoBMRNBioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan FacilityPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500%...
- 9mo agoBMRNBioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan FacilityPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850...
- 10mo agoBMRNBioMarin Appoints Arpit Davé Chief Digital and Information OfficerPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it has appointed Arpit Davé as Executive Vice President, Chief Digital and Information...
- 10mo agoBMRNBioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CAPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at...
- 10mo agoVEEVBMRNVeeva and BioMarin Form Long-Term Strategic PartnershipPR NewswireVeeva Systems (NYSE: VEEV) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced a long-term enterprise agreement that builds upon their...
- 10mo agoVEEVBMRNVeeva and BioMarin Form Long-Term Strategic PartnershipPR NewswireVeeva Systems (NYSE: VEEV) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced a long-term enterprise agreement that builds upon their...
- 10mo agoBMRNFOLDBioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial OutlookPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive...
- 1y agoBMRNBioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, EnglandPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the Jefferies Global Healthcare Conference on Tuesday,...
- 1y agoBMRNFDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with PhenylketonuriaPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the...
- 1y agoBMRNBioMarin Reports Third Quarter 2025 Results and Provides Corporate UpdatePR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2025. "We are pleased with...
- 1y agoBMRNBioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ETPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...
- 1y agoBMRNBioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoBMRNBioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual MeetingPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from 14 studies were presented at the American Society for Bone and Mineral...
- 1y agoBMRNBioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of MetabolismPR NewswireBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data characterizing the efficacy and safety of PALYNZIQ® (pegvaliase-pqpz) for the...
- 1y agoBMRNBioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)Earnings Call Transcripts
- 1y agoBMRNBioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoBMRNBioMarin to Participate in Upcoming Investor ConferencesPR NewswireBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September. An audio...